** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with "buy" rating and $8 PT; represents 161% upside to the stock's last close
** Brokerage says co is expected to see "compelling growth opportunity for 2025" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034
** Believes Anktiva can be a "backbone therapy" with a wide range of applications, but its value is "highly underappreciated"
** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage
** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer
** IBRX fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。